Nature Search

Altered histone modifications in Aedes aegypti midguts following Rift Valley fever virus exposure

Hunter A. Ogg
Zoey M. Mikol
Corey L. Campbell
ResearchOpen Access29 Jan 2026
Scientific Reports

Volume: 16, P: 1-14
Erratum: Post-exposure treatments for Ebola and Marburg virus infections

Robert W. Cross
Chad E. Mire
Thomas W. Geisbert
Amendments and Corrections04 May 2018
Nature Reviews Drug Discovery
Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA

Treatment with lipid nanoparticles encapsulating siRNAs targeting the viral VP35 gene are able to rescue rhesus macaques infected with a lethal dose of Sudan ebolavirus.

Emily P. Thi
Amy C. H. Lee
Chad E. Mire
Research22 Aug 2016
Nature Microbiology

Volume: 1, P: 1-10
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

Monoclonal antibodies show great promise in treating Covid-19 patients. Here, Maisonnasse, Aldon and colleagues report pre-clinical results for COVA1-18 and demonstrate that it reduces viral infectivity in three animal models with over 95% efficacy in macaques upper respiratory tract.

Pauline Maisonnasse
Yoann Aldon
Roger Le Grand
ResearchOpen Access20 Oct 2021
Nature Communications

Volume: 12, P: 1-10
A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection

Lassa virus infections in humans can result in severe disease, including hemorrhagic fever. Here the authors describe an mRNA-based Lassa virus vaccine that shows protection without requirement for neutralizing antibody in a guinea pig model of infection.

Adam J. Ronk
Nicole M. Lloyd
Alexander Bukreyev
ResearchOpen Access12 Sept 2023
Nature Communications

Volume: 14, P: 1-13
Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine

Modified nucleosides are often used in mRNA vaccines and can affect protein expression and immunogenicity. Here, the authors compare M segment based Andes virus mRNA vaccines, either with regular uridine or N1-methylpseudouridine, and characterize immune response and protection in rodents.

Ivan V. Kuzmin
Ruben Soto Acosta
Alexander Bukreyev
ResearchOpen Access30 Jul 2024
Nature Communications

Volume: 15, P: 1-18
Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins

Structural and functional characterization of two neutralizing antibodies that target conserved, nonoverlapping epitopes in HeV and NiV F protein trimers and inhibit membrane fusion establishes the therapeutic potential of antibody cocktails to protect against henipavirus infection.

Ha V. Dang
Robert W. Cross
David Veesler
Research29 Apr 2021
Nature Structural & Molecular Biology

Volume: 28, P: 426-434
The immunomodulating V and W proteins of Nipah virus determine disease course

Nipah virus (NiV) can be transmitted from bats and other animals to humans, causing severe encephalitis and respiratory disease. Here, Satterfield et al.show that the W protein of NiV modulates the host immune response and determines disease course in a ferret model of infection.

Benjamin A. Satterfield
Robert W. Cross
Chad E. Mire
ResearchOpen Access24 Jun 2015
Nature Communications

Volume: 6, P: 1-15
An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections

An antibody that recognizes the F glycoproteins from Nipah and Hendra viruses can neutralize both viruses and recognizes a quaternary epitope in the prefusion F trimer, preventing conformational changes required for fusion.

Ha V. Dang
Yee-Peng Chan
David Veesler
Research30 Sept 2019
Nature Structural & Molecular Biology

Volume: 26, P: 980-987
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates

Ebola-virus-targeting short interfering RNAs (siRNAs) encapsulated in lipid nanoparticles are adapted to the current outbreak strain of the virus, and the siRNA cocktail is shown to protect nonhuman primates fully when administered 3 days after challenge with the current West African Ebola virus isolate; upon viral sequence data availability, the drug can be adapted to the new virus and produced in as little as 8 weeks.

Emily P. Thi
Chad E. Mire
Thomas W. Geisbert
Research22 Apr 2015
Nature

Volume: 521, P: 362-365
Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Thomas Geisbert and colleagues show that a cocktail of monoclonal antibodies protects cynomolgus monkeys from lethal Lassa fever virus infection, including when administration is delayed by more than a week after viral challenge.

Chad E Mire
Robert W Cross
Thomas W Geisbert
Research04 Sept 2017
Nature Medicine

Volume: 23, P: 1146-1149
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus

Two second-generation attenuated Ebola virus vaccines based on recombinant vesicular stomatitis virus protect macaques against infection with a recent Ebola virus isolate from Guinea.

Chad E. Mire
Demetrius Matassov
Thomas W. Geisbert
Research08 Apr 2015
Nature

Volume: 520, P: 688-691
Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy

Chad E. Mire
Benjamin A. Satterfield
Thomas W. Geisbert
ResearchOpen Access03 Aug 2016
Scientific Reports

Volume: 6, P: 1-16
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2

Philipp A. Ilinykh
Sivakumar Periasamy
Alexander Bukreyev
ResearchOpen Access25 Apr 2022
npj Vaccines

Volume: 7, P: 1-16
Antagonism of STAT1 by Nipah virus P gene products modulates disease course but not lethal outcome in the ferret model

Benjamin A. Satterfield
Viktoriya Borisevich
Chad E. Mire
ResearchOpen Access13 Nov 2019
Scientific Reports

Volume: 9, P: 1-18
A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19

Delphine C. Malherbe
Drishya Kurup
Alexander Bukreyev
ResearchOpen Access22 Jul 2021
npj Vaccines

Volume: 6, P: 1-11
Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever

Sergio E. Rodriguez
Robert W. Cross
Thomas W. Geisbert
ResearchOpen Access23 May 2019
Scientific Reports

Volume: 9, P: 1-13
Post-exposure treatments for Ebola and Marburg virus infections

Efforts towards developing post-exposure therapies for infections with filoviruses, particularly Ebola and Marburg viruses, increased substantially during the Ebola virus outbreak of 2013–2016. Geisbert and colleagues review the progress made on this front and discuss the challenges and opportunities for developing post-exposure therapies in the future.

Robert W. Cross
Chad E. Mire
Thomas W. Geisbert
Reviews29 Jan 2018
Nature Reviews Drug Discovery

Volume: 17, P: 413-434
Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge

Teresa E. Sorvillo
Robert W. Cross
Thomas W. Geisbert
ResearchOpen Access09 Aug 2021
npj Vaccines

Volume: 6, P: 1-8
Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants

Krista Versteeg
Andrea R. Menicucci
Thomas W. Geisbert
ResearchOpen Access29 Aug 2017
Scientific Reports

Volume: 7, P: 1-16
Immune correlates of postexposure vaccine protection against Marburg virus

Courtney Woolsey
Allen Jankeel
Thomas W. Geisbert
ResearchOpen Access20 Feb 2020
Scientific Reports

Volume: 10, P: 1-18
Author Correction: Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants

Krista Versteeg
Andrea R. Menicucci
Thomas W. Geisbert
Amendments and CorrectionsOpen Access08 May 2019
Scientific Reports

Volume: 9, P: 1-4

Search

Altered histone modifications in Aedes aegypti midguts following Rift Valley fever virus exposure

Erratum: Post-exposure treatments for Ebola and Marburg virus infections

Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection

Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine

Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins

The immunomodulating V and W proteins of Nipah virus determine disease course

An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus

Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy

A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2

Antagonism of STAT1 by Nipah virus P gene products modulates disease course but not lethal outcome in the ferret model

A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19

Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever

Post-exposure treatments for Ebola and Marburg virus infections

Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge

Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants

Immune correlates of postexposure vaccine protection against Marburg virus

Author Correction: Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants

Search

Quick links

Search

Filter By:

Search

Quick links